<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03195023</url>
  </required_header>
  <id_info>
    <org_study_id>PROERCAN01</org_study_id>
    <nct_id>NCT03195023</nct_id>
  </id_info>
  <brief_title>Effect of RAS Blockers on Chronic Kidney Disease Progression in Elderly Patients With Non Proteinuric Nephropathies</brief_title>
  <acronym>PROERCAN01</acronym>
  <official_title>Effect of Renin-angiotensin System Blocker Drugs on Chronic Kidney Disease Progression in Elderly Patients With Non Proteinuric Nephropathies (PROERCAN01)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital General Universitario Gregorio Marañon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital General Universitario Gregorio Marañon</source>
  <brief_summary>
    <textblock>
      This study evaluates the effect of renin-angiotensin blockers on chronic kidney disease
      progression in elderly (&gt;65 years old) patients with non-proteinuric nephropathies. Half of
      the patients will receive angiotensin converting enzyme inhibitors, while the other half will
      not receive them. Renal function, proteinuria and cardiovascular events will be follow up
      during a three year period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STUDY DESIGN: Open, multicentre, prospective, parallel-group, randomized controlled study
      comparing the effect of an angiotensin converting enzyme inhibitor (ACEI) vs standard
      antihypertensive treatment without ACEI, in the progression of renal disease in elderly
      patients with non-proteinuric 3-4 stage chronic renal disease.

      Elderly patients (&gt; 65 years) with moderate-severe non-proteinuric chronic renal disease
      (estimated Glomerular Filtrate Rate between 19-59 ml per minute per 1.73 m2 using the Chronic
      Kidney Disease Epidemiology Collaboration Group equation) and urine-creatinine rate &lt; 30
      mg/g, will be included. They will be randomly assigned in a 1:1 ratio to receive ACEI or
      standard antihypertensive treatment. Patients will be followed up for 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Chronic kidney disease progression</measure>
    <time_frame>3 years</time_frame>
    <description>Increase of baseline creatinine during follow up period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Security of RAS blockers in elderly patients</measure>
    <time_frame>3 YEARS</time_frame>
    <description>Evaluate the frequency of hiperpotassemia (K&gt;5.5 mmol/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Security of RAS blockers in elderly patients</measure>
    <time_frame>3 YEARS</time_frame>
    <description>Evaluate the frequency of acute kidney failure (&gt;Cr 0.3 mg/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of RAS blockers on mortality in elderly patients</measure>
    <time_frame>3 YEARS</time_frame>
    <description>Evaluate the number and cause of deaths in the study population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of RAS blockers on cardiovascular risk in elderly patients</measure>
    <time_frame>3 YEARS</time_frame>
    <description>Evaluate and classify cardiovascular events (heart failure, acute coronary syndrome, peripheral vasculopathy) during the follow up period</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">106</enrollment>
  <condition>Renal Insufficiency, Chronic</condition>
  <condition>Proteinuria</condition>
  <arm_group>
    <arm_group_label>RAS Blockers</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this arm will receive Lisinopril 20mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non RAS Blockers</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this arm will receive Amlodipine 10mg/day or Lercanidipine 20mg/day +/- diuretics</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lisinopril</intervention_name>
    <arm_group_label>RAS Blockers</arm_group_label>
    <other_name>Angiotensin converting enzyme inhibitors</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine</intervention_name>
    <description>Patients in this arm will receive antihypertensive treatment different from RAS blockers. If they previously received RAS blockers, they will be substitute for either Amlodipine or Lercanidipine +/- diuretics</description>
    <arm_group_label>Non RAS Blockers</arm_group_label>
    <other_name>Lercanidipine, Furosemide, Thiazides</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;65 years

          -  Chronic kidney disease stage 3 or 4 (GFR measured by CKD-EPI 15-59 ml/min/1,73 m2)

          -  Albumine/creatinine index &lt; 30 mg/g in simple urine sample or albuminuria &lt; 30 mg/day
             in 24-hour urine sample.

          -  Previous hypertensive treatment::

               1. patients who have not received RAS blockers in the three months prior to
                  inclusion can be included

               2. patients who are receiving RAS blockers could be included after one month washout
                  period

        Exclusion Criteria:

          -  Diabetes mellitus (type 1 or 2)

          -  Glomerulopathy

          -  Chronic heart failure or coronary heart disease

          -  Poorly controlled hypertension (&gt;160/100 mmHg)

          -  Active malignant neoplasia (except skin cancer different from melanoma). Patients who
             have been free of malignancy for the last 5 years could be included.

          -  Chronic symptomatic or not controlled inflammatory disease (eg rheumatoid arthritis,
             Chron disease, ulcerative colitis or systemic lupus erythematosus)

          -  Chronic liver disease

          -  Allergy or intolerance to renin angiotensin system blockers or calcium channel
             blockers

          -  Hepatitis B, C or HIV infection

          -  Immunosuppressive treatment in the 3 months prior to inclusion

          -  Hospitalization of any cause in the three months prior to inclusion

          -  Rapidly progressive kidney disease (decline in GFR &gt;5ml/min/1.73 m2/year)

          -  Inability to sign the informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Angeles Goicoechea, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital General Universitario Gregorio Marañon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria Angeles Goicoechea, PhD, MD</last_name>
    <phone>0034609838684</phone>
    <email>marian.goicoechea@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ana Maria Garcia Prieto, MD</last_name>
    <phone>0034676611045</phone>
    <email>anamgarciaprieto@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gregorio Maranon Hospital</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Angeles Goicoechea, PhD, MD</last_name>
      <phone>0034609838684</phone>
      <email>marian.goicoechea@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Ana María García, MD</last_name>
      <phone>0034676611045</phone>
      <email>anamgarciaprieto@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, de Zeeuw D, Shahinfar S, Toto R, Levey AS; AIPRD Study Group. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med. 2003 Aug 19;139(4):244-52.</citation>
    <PMID>12965979</PMID>
  </reference>
  <reference>
    <citation>Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG; African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002 Nov 20;288(19):2421-31. Erratum in: JAMA. 2006 Jun 21;295(23):2726.</citation>
    <PMID>12435255</PMID>
  </reference>
  <reference>
    <citation>O'Hare AM, Kaufman JS, Covinsky KE, Landefeld CS, McFarland LV, Larson EB. Current guidelines for using angiotensin-converting enzyme inhibitors and angiotensin II-receptor antagonists in chronic kidney disease: is the evidence base relevant to older adults? Ann Intern Med. 2009 May 19;150(10):717-24.</citation>
    <PMID>19451579</PMID>
  </reference>
  <reference>
    <citation>Ahmed AK, Kamath NS, El Kossi M, El Nahas AM. The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease. Nephrol Dial Transplant. 2010 Dec;25(12):3977-82. doi: 10.1093/ndt/gfp511. Epub 2009 Oct 10.</citation>
    <PMID>19820248</PMID>
  </reference>
  <reference>
    <citation>Weiss JW, Thorp ML, O'Hare AM. Renin-angiotensin system blockade in older adults with chronic kidney disease: a review of the literature. Curr Opin Nephrol Hypertens. 2010 Sep;19(5):413-9. doi: 10.1097/MNH.0b013e32833b8d6b. Review.</citation>
    <PMID>20539228</PMID>
  </reference>
  <reference>
    <citation>Turgut F, Balogun RA, Abdel-Rahman EM. Renin-angiotensin-aldosterone system blockade effects on the kidney in the elderly: benefits and limitations. Clin J Am Soc Nephrol. 2010 Jul;5(7):1330-9. doi: 10.2215/CJN.08611209. Epub 2010 May 24. Review.</citation>
    <PMID>20498247</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2017</study_first_submitted>
  <study_first_submitted_qc>June 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2017</study_first_posted>
  <last_update_submitted>June 19, 2017</last_update_submitted>
  <last_update_submitted_qc>June 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital General Universitario Gregorio Marañon</investigator_affiliation>
    <investigator_full_name>Maria Maria Angeles Goicoechea Diezhandino</investigator_full_name>
    <investigator_title>Nefrologist</investigator_title>
  </responsible_party>
  <keyword>Renal Insufficiency, Chronic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
    <mesh_term>Proteinuria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lercanidipine</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Lisinopril</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
    <mesh_term>Enzyme Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

